We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Panel Improves Diagnosis of Candida in Pediatric Patients

By LabMedica International staff writers
Posted on 15 Jul 2015
Print article
In an investigational study of pediatric patients, a Candida test panel provided accurate, fast diagnosis with only 2 mL of blood.

Rapid detection of Candida enables faster initiation of targeted treatment and can reduce a patient's length of hospitalization by almost 9 days. A rapid negative result can prevent unnecessary administration of antimicrobials as well as prevent or reduce antimicrobial resistance.

T2 Biosystems, Inc. (Lexington, MA, USA) presented results from an investigational study evaluating its T2Candida Panel in pediatric patients at the 2015 American Society for Microbiology (ASM) general meeting in New Orleans (LA, USA). The study included 15 confirmed candidemia patients 5–12 years of age. The data presented showed that in each of the 15 patient samples, T2Candida was able to accurately identify the species in 3–5 hours, compared to 2–6 days for blood culture. For this study a manual pipetting protocol was adapted to enable detection from just 2 mL of blood compared to the 3 mL currently required for the standard loading procedure.

"Fast and accurate results have been a challenge to obtain in pediatric patients suspected of sepsis due to the volume of blood required by current diagnostic procedures," said Prof. Camille Hamula, Icahn School of Medicine, Mount Sinai Hospital, "This new loading procedure maintains the high accuracy and fast results of the T2Candida Panel but with lower sample volume, which could have an important impact on the lives of young patients at risk of sepsis." "We are encouraged by these findings demonstrating that our T2Candida Panel was able to provide accurate results from lower blood volumes, which is critical in the pediatric patient population," said John McDonough, T2 Biosystems president and CEO.

T2Candida Panel, the first sepsis pathogen diagnostic that provides species-specific results in 3–5 hours without need for blood culture, was cleared for marketing by the US Food and Drug Administration (FDA) in September 2014. T2Candida Panel performance was established in adult subjects; performance in neonates, infants, and pediatric patients has not been established.

Related Links:

T2 Biosystems
ASM 2015 presentation of study results

Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
Platinum Supplier
Diagnostic Reader
Acucy System
Herpes Simplex Virus Test
S3002E HSV-2

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.